Barquet Luis Arias
Jefe de Sección de Retina y Vítreo, del Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España; Profesor Asociado de la Universidad de Barcelona, Barcelona, España; Sociedad Española de la Retina y Vítreo, Instituto de Salud Carlos III, Madrid, España; Red Temática de Investigación Cooperativa OFTARED, Instituto de Salud Carlos III, Madrid, España.
Arch Soc Esp Oftalmol. 2015 Mar;90 Suppl 1:3-5. doi: 10.1016/S0365-6691(15)30002-2.
Angiogenesis is the process through which new blood vessels are formed, based on preexisting vessels, and is the paradigm of diseases such as cancer and exudative ageassociated macular degeneration (ARMD). Several proangiogenic factors have been identified, such as vascular endothelial growth factor (VEGF), especially VEGF-A, which activates endothelial cells and promotes cell proliferation, migration, and an increase in vascular permeability. VEGF is also involved in the etiopathogenesis of other retinal diseases, such as diabetic macular edema and macular edema secondary to retinal vein occlusion. Likewise, there is increasing evidence that placental growth factor (PIGF) acts recepsynergetically with VEGF in promoting these diseases. Currently, the main treatment for these diseases are the anti-VEGF drugs, aflibercept, ranibizumab and bevacizumab. These agents differ in their molecular structure and mechanism of action.
血管生成是基于已有的血管形成新血管的过程，是癌症和渗出性年龄相关性黄斑变性（ARMD）等疾病的典型特征。已经确定了几种促血管生成因子，如血管内皮生长因子（VEGF），尤其是VEGF-A，它激活内皮细胞并促进细胞增殖、迁移以及血管通透性增加。VEGF还参与其他视网膜疾病的发病机制，如糖尿病性黄斑水肿和视网膜静脉阻塞继发的黄斑水肿。同样，越来越多的证据表明胎盘生长因子（PIGF）在促进这些疾病方面与VEGF协同作用。目前，这些疾病的主要治疗方法是抗VEGF药物，阿柏西普、雷珠单抗和贝伐单抗。这些药物在分子结构和作用机制上有所不同。
